Aktieanalys

Ascelia Pharma Q1: Progress towards submission and partner discussions - Redeye

{newsItem.title}

Redeye Publicerad: 16 May 2024 08:57

Ascelia’s actual Q1 result is a very minor event compared with the recent SPARKLE success. Ascelia is preparing for submission by mid-2025, and Ascelia’s cost base is contained. Our Base Case is SEK 17 (Bull SEK 45 and Bear SEK 6).

Länk till analysen i sin helhet: https://www.redeye.se/research/1008219/ascelia-pharma-q1-progress-towards-submission-and-partner-discussions?utm_source=finwire&utm_medium=RSS

Nyheter om Ascelia Pharma

Läses av andra just nu

Om aktien Ascelia Pharma

Senaste nytt